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We investigated possible interactions between HIV-1 receptor (CD4) and the main coreceptors CXCR4 and CCR5. We found that CD4 and
CXCR4 coexpressed in 293T cells form a complex that can be immunoprecipitated with antibodies directed against the extracellular domain of
either protein. Mutagenesis revealed that the CD4/CXCR4 interaction maps to two previously uncharacterized basic motifs in the cytoplasmic
domain of CD4. HIV-1 envelope glycoprotein-mediated membrane fusion was found to be independent of the ability of CD4 and CXCR4 to
interact, whether fusion was studied in a virus–cell or a cell–cell model. However, this interaction might explain the adaptation of HIV-1 to
CXCR4 as an alternative to CCR5. We found that CXCR4 also interacts with the cytoplasmic domain of CD8α in a way that is similar to the CD4/
CXCR4 interaction. The CD4/CXCR4 and CD8α/CXCR4 interactions may thus be involved in cellular signaling pathways shared by the CD4
and CD8α molecules.
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Human immunodeficiency virus type 1 (HIV-1) entry into
target cells requires the fusion of viral and cellular membranes.
This event is initiated by the successive binding of the surface
subunit of HIV-1 envelope glycoprotein (gp120) to CD4, which
is the primary receptor for HIV-1 (Dalgleish et al., 1984;
Klatzmann et al., 1984) and a coreceptor belonging to the
family of chemokine receptors, mainly CXCR4 or CCR5
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doi:10.1016/j.virol.2006.05.027et al., 1996; Wu et al., 1996), expressed on the target cell
surface. The chemokine receptors are part of a much larger
family of G-protein-coupled receptors (GPCRs). CCR5-using
viruses are responsible for most cases of viral transmission and
persist throughout the course of HIV-1 infection (van't Wout et
al., 1994; Zhu et al., 1993). The emergence of CXCR4-using
viruses and dual-tropic viruses occurs later in the course of HIV-
1 infection, but the biological reasons for the switch for this
alternative coreceptor are uncertain (Alkhatib et al., 1996; Choe
et al., 1996; Glushakova et al., 1999; Miedema et al., 1994).
Although the vast majority of HIV-1 strains are strictly CD4-
dependent, a few reports describe CD4-independent HIV-1
isolates capable of using CD8 as a primary receptor on cytotoxic
T cells (Saha et al., 2001a, 2001b; Zerhouni et al., 2004a,
2004b). The fact that CD4 and CD8 might have similar
functions as HIV-1 primary receptors, at least for some
particular strains, echoes their similar role in the assembly of
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(APC) and helper or cytotoxic T cells, respectively [for reviews,
see references (Gao et al., 2002; Gascoigne and Zal, 2004]. CD4
expressed on T helper cells tethers the complex involving
peptide-loaded MHC-II molecules on APCs and the T cell
receptor (TCR) by interacting with non-polymorphic regions of
MHC-II molecules (Doyle and Strominger, 1987). Similarly,
CD8 expressed on cytotoxic T cells interacts with non-
polymorphic regions of MHC-I molecules and contributes to
the stabilization of the interaction between peptide-loaded
MHC-I molecules and the T cell receptor (Norment et al., 1988).
CD4 and CD8 also share the ability to interact with the Lck
tyrosine kinase through their cytoplasmic domains (Barber et
al., 1989; Kim et al., 2003; Veillette et al., 1988). Thus, in
addition to their involvement in the assembly of the
immunological synapse, CD4 and CD8 actively contribute to
the signal transduction cascade by bringing Lck to the forming
synapse (Li et al., 2004; McGavern et al., 2002).
Not much is known about the mechanism by which some
HIV-1 strains use CD8 for entry. On the contrary, the
involvement of CD4 in entry has been extensively character-
ized. The gp120/CD4 interaction has been shown to involve
discontinuous epitopes on both molecules (Kwong et al., 1998;
Wyatt et al., 1998) and provokes important structural changes in
gp120 (Myszka et al., 2000). These structural changes result in
the exposure of CD4-induced (CD4i) epitopes (Sattentau and
Moore, 1991; Thali et al., 1993) and increase the affinity of the
CD4-bound gp120 for its cognate coreceptor. Further studies
mapped the coreceptor-binding site on gp120 to the third
variable loop (V3) and the β19 strand (Basmaciogullari et al.,
2002; Hwang et al., 1991; Rizzuto and Sodroski, 2000; Rizzuto
et al., 1998; Speck et al., 1997).
Because gp120 has distinct interaction sites for CD4 and a
coreceptor and can accommodate both molecules, the assembly
of the gp120/CD4/coreceptor trimolecular complex has long
been considered to be governed by the scaffolding properties of
gp120. However, a growing body of evidence suggests a
possible interaction between CD4 and HIV-1 coreceptors
(Lapham et al., 1999, 2002; Mbemba et al., 2002; Sloane et
al., 2005; Ugolini et al., 1997; Xiao et al., 1999, 2003; Zaitseva
et al., 2005).
In this study, we analyze the ability of CD4 to interact with
CXCR4 and CCR5 by coprecipitation experiments and map
regions on the proteins critical for the observed interactions. We
find that CXCR4 efficiently interacts with CD4 and also with
CD8α. At least under the conditions tested, the CD4/CXCR4
interaction did not affect the efficiency of HIV-1 envelope-
mediated membrane fusion.
Results
Interaction between CD4 and CXCR4
The ability of CD4 to interact with the two main HIV-1
coreceptors, CCR5 and CXCR4, was investigated by immuno-
precipitation of cleared lysates from 293T cells transiently
coexpressing CD4 with CXCR4 or CCR5. The C5aR was alsoincluded in our study as a control GPCR that is not a coreceptor
for HIV-1. Transfected cells were metabolically labeled with
35S-Cys and -Met and lysed; either CD4 or the GPCRs were
immunoprecipitated. The immunoprecipitated material was
then resolved by SDS-PAGE under non-reducing conditions.
As shown in Fig. 1A, the immunoprecipitation of CXCR4 from
a lysate of cells coexpressing CD4 and CXCR4 resulted in the
coprecipitation of a protein with the same mobility as that of a
CD4 dimer (compare lanes 1 and 3). Unlike the situation with
CXCR4, the CCR5 and C5aR immunoprecipitations invariably
resulted in higher background when equivalent amounts of
immunoprecipitated GPCR were achieved and did not allow us
to reach conclusions about the coprecipitation of CD4. To
circumvent this problem, the formation of a complex between
CD4 and the above GPCRs was investigated by analyzing the
molecular species coprecipitated using an anti-CD4 antibody.
As can be seen from Fig. 1A, the immunoprecipitation of CD4
also revealed the coprecipitation of a protein with the same
mobility as that of CXCR4 when cells coexpressed CD4 and
CXCR4 (compare lanes 1 and 4). No coprecipitation was seen
when cells coexpressed CD4 and CCR5 or C5aR (lanes 7 and
10, respectively). These results show that a CD4/CXCR4
complex can be immunoprecipitated from cells coexpressing
both proteins. Neither a CD4/CCR5 nor a CD4/C5aR complex
was detected using the same experimental conditions.
We examined the ability of CD4 and CXCR4 to form a
complex in cells that naturally express these proteins. Jurkat T
cells that express both CD4 and CXCR4 (Fig. 1B) were
solubilized and the CD4/CXCR4 complex was analyzed by
immunoprecipitation followed by Western blotting. None of
several CXCR4-specific antibodies that we tried were able to
detect CXCR4 by Western blotting. We thus investigated the
formation of a CD4/CXCR4 complex by CXCR4 immunopre-
cipitation followed by CD4 immunodetection. As can be seen
from Fig. 1C, CD4 was coprecipitated with CXCR4 from a
cleared lysate of Jurkat cells (lower panel, lane 1). CD4 was also
coprecipitated with CXCR4 in 293T cells cotransfected with
plasmids encoding CD4 and CXCR4 (lane 2), confirming the
data shown in Fig. 1A. No CD4 was detected when the
immunoprecipitations were carried out using cells expressing
CD4 or CXCR4 alone (lanes 3 and 4, respectively). These data
show that an interaction between CD4 and CXCR4 can be
detected in cells naturally expressing these proteins and that
coexpression in 293T cells represents a useful system to dissect
the mechanism of this interaction.
CXCR4 interacts with the cytoplasmic domains of CD4 and
CD8α
To identify the regions of CD4 involved in the CD4/CXCR4
interaction, CXCR4 was expressed along with chimerae
composed of the cytoplasmic, transmembrane and extracellular
domains of CD4 and CD8α. Immunoprecipitation of the
chimerae with antibodies specific for their extracellular domains
invariably resulted in the coprecipitation of CXCR4, except
when cytoplasmic tail-deleted mutants were used (not shown).
This suggested that CD4 and CD8α can form a complex with
Fig. 1. Immunoprecipitation of a CD4/CXCR4 complex from transfected 293T and Jurkat T cells. (A) Transfected 293T cells expressing or coexpressing the indicated
proteins were metabolically labeled with 35S-Cys and -Met and solubilized. Cleared lysates containing ∼800 μg of total proteins were incubated for 2 h with protein
A–Sepharose beads and the following mAbs: anti-CD4 (OKT4, 2 μg), anti-CXCR4 (12G5, 2 μg), anti-CCR5 (2D7, 2 μg) or anti-C5aR (C85-4124, 20 μl) as indicated
on the bottom of the figure. Immunoprecipitated proteins were resolved by 10% acrylamide Tris–glycine SDS-PAGE and visualized by fluorography. The molecular
weights in kDa of standard proteins are indicated on the left. (B) Flow cytometry analysis of CD4 and CXCR4 cell surface expression in Jurkat T cells. Upper panel:
dotted line, no primary Ab; plain line, IgG2b (200 nM); filled histogram, OKT4 (200 nM). Lower panel: dotted line, no primary Ab; plain line, IgG2a (200 nM); filled
histogram, 12G5 (200 nM). (C) CXCR4 immunoprecipitations (lower panel) were performed with 2 μg of 12G5 on cleared lysates of Jurkat cells (∼16,000 μg of total
proteins) and transfected 293T cells expressing or coexpressing the indicated proteins (∼800 μg of total proteins). Cleared lysate containing 160 μg and 20 μg of total
proteins from Jurkat and transfected 293T cells, respectively, were also analyzed to visualize CD4 expression levels in these cells (upper panel). Proteins were resolved
by SDS-PAGE and visualized by Western blotting followed by immunodetection.
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CD8α may be involved in the interaction with CXCR4. To test
this hypothesis, full-length or ΔCT1 CD4 and CD8α (Fig. 2)
were coexpressed with CXCR4 or CCR5 in 293T cells. CD4
and CD8α were then immunoprecipitated from cleared lysates,
and the coprecipitation of CXCR4 or CCR5 was investigated by
Western blotting, using the 1D4 antibody specific for the C9 tag
added at the C-terminus of the GPCRs. Fig. 3A shows that
CXCR4 molecules were coprecipitated with CD4 but not with
CD4 ΔCT1 (lanes 3 and 4, respectively). No CXCR4 was
coprecipitated from a lysate of cells expressing CXCR4 alone
(lane 2). Similarly, CXCR4 was coprecipitated with CD8α but
not with CD8 ΔCT1 (Fig. 3B, lanes 3 and 4, respectively). By
contrast, no significant CCR5 coprecipitation was detected with
any of the CD4 or CD8 constructs (Fig 3A and 3B, lanes 7 and
8). These results demonstrate that the cytoplasmic domains of
both CD4 and CD8α are important for the formation of a
complex with CXCR4.The CD4/CXCR4 and CD8α/CXCR4 interactions can be
reconstituted when proteins are expressed separately and the
cell lysates mixed
The observed coprecipitation of CXCR4 with CD4 and
CD8α during the coexpression of these proteins could
hypothetically reflect the precipitation of incompletely solubi-
lized patches of CXCR4-containing membrane surrounding
wild-type CD4 and CD8α. The following experiment was
performed to address this issue. CXCR4 and CD4 were either
coexpressed or expressed separately in two distinct populations
of 293T cells by transfection. In the latter case, cells were either
mixed and lysed or lysed separately. As shown in Fig. 4A, the
immunoprecipitation of CD4 from a lysate of cells coexpressing
CD4 and CXCR4 efficiently coprecipitated CXCR4 (lane 1), as
observed previously. The expression of CD4 and CXCR4 in
two distinct populations of 293T cells also resulted in the
formation of a CD4/CXCR4 complex immunoprecipitated by
Fig. 2. Transmembrane and cytoplasmic domains of wild-type and mutant proteins used in this study. The transmembrane and cytoplasmic domains of full-length,
truncated, and mutant forms of CD4 and CD8α are illustrated. Single amino-acid substitutions are indicated. The arginine-rich motif found in the membrane proximal
cytoplasmic domain of CD4 and CD8α is underlined. The transmembrane and cytoplasmic domains of CD4, CD8α and CD4/CD3 chimeric constructs are also
represented. Interaction between the CD4 and CD8 variants and CXCR4 is summarized in the right hand column.
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mixed and lysed together (lane 2) or when cells were lysed
separately and the immunoprecipitation conducted on a 1:1 mix
of the two cleared lysates (lane 3). Interestingly, protein A–
Sepharose beads coated with an OKT4-CD4 complex were not
able to coprecipitate CXCR4 when incubated with a cleared
lysate of cells transfected with CXCR4 alone (lane 4); similar
amounts of CD4 were immunoprecipitated under these
circumstances as in experiments where CXCR4 coprecipitation
was detected (Fig. 4A, lower panel). We also analyzed the
formation of the CD4/CXCR4 complex by incubating intact
cells with OKT4. The cells were then solubilized and the OKT4/
CD4 complex was captured by adding protein A–Sepharose
beads to the cleared lysates. In these conditions, efficient
coimmunoprecipitation of CXCR4 was detected (data not
shown), suggesting that the CD4/CXCR4 complex is present
at the plasma membrane. CXCR4 coprecipitation with CD8α
was demonstrated, using an experimental system similar to that
used to study the CD4/CXCR4 interaction (Fig. 4B). These
results confirm that the CXCR4 coprecipitation with CD4 and
CD8α reflects a strong interaction rather than partial lysis of cell
membranes under our experimental conditions.
Because protein A–Sepharose beads coated with an OKT4-
CD4 complex did not coprecipitate CXCR4, we wished to
determine whether the binding of OKT4 to CD4 or the
immobilization of CD4 on protein A–Sepharose beads
prevented the formation of the CD4–CXCR4 complex. Tothis end, CD4 and CXCR4 were separately expressed in distinct
transfections, the cells were lysed and the CD4–CXCR4
complex was allowed to form by mixing the respective cell
lysates under different conditions. Fig. 4C shows that the
preincubation of CD4-containing lysate with CXCR4-contain-
ing lysate, followed by the addition of OKT4 or Q4120 and
protein A–Sepharose beads resulted in a successful CXCR4
coprecipitation with CD4 (lanes 1 and 4, respectively). A much
less efficient coprecipitation was seen when the antibody–CD4
complex was allowed to form prior to the addition of the
CXCR4-containing lysate and protein A–Sepharose beads
(lanes 2 and 5), even though the same amounts of lysates
were used. Consistent with our previous results (see lane 4 in
Fig 4A), no detectable CXCR4 was coprecipitated when CD4-
coated protein A–Sepharose beads were incubated with a
CXCR4-containing lysate (lanes 3 and 6). These data
demonstrate that although OKT4 and Q4120 can immunopre-
cipitate the CD4/CXCR4 complex, once CD4 is bound to any of
these antibodies, the formation of the complex with CXCR4 is
very inefficient. Subsequent coimmunoprecipitation experi-
ments described below were thus conducted by mixing and
incubating lysates containing proteins of interest prior to the
addition of the antibodies and protein A–Sepharose beads. Of
note, the fact that no CXCR4 coprecipitation was seen with an
antibody directed against the cytoplasmic domain of CD4 (Fig.
4C, lanes 7–9) further supported the involvement of the
cytoplasmic domain of CD4 in the CD4/CXCR4 interaction.
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To examine the specificity of the interaction of CXCR4 with
CD4 and CD8α, additional Type 1 transmembrane (1-TM)
proteins (MHC-II proteins and IL2Rα) were used in copreci-
pitation assays with CXCR4, CCR5 and C5aR. The proteins of
interest were expressed separately in transfected 293T cells, and
cleared lysates were mixed for coprecipitation experiments. In
the assay described in Fig. 5A, a fixed amount of 1-TM-
containing lysate was incubated with increasing amounts of
GPCR-containing lysate. The 1-TM proteins were immunopre-
cipitated and resolved by SDS-PAGE; any coprecipitated
GPCRs were detected by Western blotting with the 1D4
antibody. A preliminary experiment was conducted to ensure
that all of the 1-TM proteins were expressed efficiently (not
shown). As can be seen from Fig. 5A, and in agreement with ourFig. 3. Involvement of the cytoplasmic domains of CD4 and CD8α in the
interaction with CXCR4. Investigation of the CD4/GPCRs (A) and CD8α/
GPCRs (B) interactions. Transfected 293T cells expressing or coexpressing the
indicated proteins were solubilized and immunoprecipitation were performed on
cleared lysates containing ∼400 μg of total proteins with 2 μg of the following
mAbs: anti-CXCR4 (12G5), anti-CCR5 (2D7) and anti-CD4 (OKT4) or anti-
CD8 (32-M4) as indicated. Proteins were resolved by SDS-PAGE and visualized
by Western blotting followed by immunodetection.
Fig. 4. Sequential immunoprecipitation of the CD4/CXCR4 and CD8α/CXCR4
complexes. (A) Lane 1: transfected 293T cells coexpressing CD4 and CXCR4
were mixed with mock-transfected cells (∼1 × 106 cells from each transfection),
incubated 1 h at 4 °C under gentle agitation and solubilized in 200 μl of
solubilization buffer. The entire cleared lysate (∼1 mg of total proteins) was
used to immunoprecipitate CD4 with 3 μg of OKT4. Lanes 2–4: CD4 and
CXCR4 were individually expressed in distinct transfected cells. The cells
(∼1 × 106 from each transfection) were either mixed and solubilized in 200 μl of
solubilization buffer (lane 2), or solubilized separately in 100 μl of solubilization
buffer, with the cleared lysates combined and incubated 1 h at 4 °C (lane 3). In
both cases, the entire cleared lysates were used to immunoprecipitate CD4 with
3 μg of OKT4. Alternatively, CD4- and CXCR4-containing lysates were
prepared separately and CD4 was immunoprecipitated from the CD4-containing
lysate with 3 μg of OKT4. The beads were then washed and incubated further for
1 h with the CXCR4-containing lysate (lane 4). Either 30 or 60% of the
precipitated material was resolved by SDS-PAGE on two separate gels and
analyzed by Western blotting for CXCR4 (upper panel, no β-ME) and CD4
(lower panel, with β-ME), respectively. (B) The interaction between CD8α and
CXCR4 was investigated as described in panel A. CD8α was immunopreci-
pitated with 3 μg of 32-M4 and analyzed under non-reducing conditions. (C)
Transfected 293T cells expressing CXCR4 or CD4 were solubilized separately
and the corresponding cleared lysates used in coprecipitation experiments as
follows. Lane 1: CXCR4- and CD4-containing lysates (∼400 μg of total
proteins each) were combined and incubated 1 h at 4 °C under gentle agitation
prior to the addition of 3 μg of OKT4. After a 1-h incubation, protein A–
Sepharose beads were added to precipitate the immune complex. Lane 2: the
CD4-containing lysate (∼400 μg of total proteins) was incubated 1 h at 4 °C
under gentle agitation in the presence of 3 μg of OKT4 prior to the addition of
the CXCR4-containing lysate (∼400 μg of total proteins). After a 1-h incubation,
protein A–Sepharose beads were added to precipitate the immune complex.
Lane 3: CD4 was immunoprecipitated from the CD4-containing lysate
(∼400 μg of total proteins) with 3 μg of OKT4 as described above. The
beads were then washed and incubated further with the CXCR4-containing
lysate (∼400 μg of total proteins). Lanes 4–6 and 7–9: the same experimental
procedures described for lanes 1–3 were used, except that the anti-CD4 mAbs
were: QS4120 (lanes 4–6) and C-18 (lanes 7–9). The immunoprecipitated
material was analyzed as described in panel A.
Fig. 5. Specificity of the CD4/CXCR4 and CD8α/CXCR4 interactions. The specified GPCRs (CXCR4, CCR5, C5aR) and 1-TM proteins (CD4, CD488, CD433,
CD8α, MHC-II molecules, IL2Rα) were individually expressed in transfected 293Tcells. Cells were solubilized separately and the corresponding cleared lysates were
then used in coprecipitation experiments as follows. (A) Upper panel: fixed amounts of the CD4-containing lysate were incubated 1 h in the presence of increasing
amounts of the CXCR4-, CCR5- or C5aR-containing lysates (lanes 1–3, 4–6, 7–8, respectively). Protein A–Sepharose beads and 2 μg of OKT4 were then added to
immunoprecipitate CD4. The precipitates were resolved by SDS-PAGE and analyzed by Western blotting to visualize the coprecipitated GPCRs. The same
experimental procedure was used to analyze the coprecipitation of GPCRs with CD8α, MHC-II molecules and IL2Rα (lower panels). The amounts of CD4-, CD8α-,
MHC-II molecules- and IL2Rα-containing lysates used in this experiment represented ∼300, 60, 130 and 300 μg of total proteins, respectively, and allowed the
immunoprecipitation of comparable amounts of the corresponding 1-TM proteins (data not shown). The range of GPCR-containing lysates used represented∼30, 100
and 300 μg of total proteins for CXCR4 and ∼100, 300 and 1000 μg of total proteins for both CCR5 and C5aR. (B) CXCR4, CCR5- and C5aR were
immunoprecipitated with 2 μg of 12G5 (lanes 1–3), 2 μg of 2D7 (lanes 4–6) and 20 μl of C85-4124 (lanes 7–9), respectively, using the same amounts of GPCR-
containing lysates as were used in panel A. The immunoprecipitated proteins were resolved by SDS-PAGE and analyzed by Western blotting to visualize the GPCRs.
(C) Fixed amounts of the CD4-containing lysate were incubated 1 h with increasing amounts of the CXCR4-containing lysates (lanes 1–3). Protein A–Sepharose
beads and 2 μg of OKT4 were then added to immunoprecipitate CD4. The precipitates were analyzed as described in the Fig. 4A legend. The same experimental
procedure was used to analyze the coprecipitation of CXCR4 with CD488 and CD433 (lanes 4–6 and 7–9, respectively). The amounts of CD4-, CD488- and CD433-
containing lysates used in this experiment represented∼200, 200 and 1800 μg of total proteins, respectively. The amount of CXCR4-containing lysate was the same as
described in panel A.
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seen with CD4 (IP CD4, lanes 1–3). Moreover, the amount of
CXCR4 coprecipitated was proportional to the input of
CXCR4. Little or no coprecipitation could be detected when
CCR5 or C5aR were used instead of CXCR4 (lanes 4–6 and 7–
9, respectively). This could not be attributed to major
differences in the amount of GPCR used in the coprecipitation
assay; the direct immunoprecipitation of CXCR4, CCR5 and
C5aR with specific antibodies followed by Western blotting and
immunodetection with the 1D4 mAb revealed that similar
ranges of input GPCR were used in this assay (Fig. 5B). A
coprecipitation of CXCR4 but neither CCR5 nor C5aR was also
seen when CD8α was used instead of CD4 (Fig. 5A, IP CD8).
No coprecipitation could be detected either with MHC-II
molecules or IL2Rα (Fig. 5A, IP MHC-II and IP IL2Rα,
respectively). This shows that the ability to interact withCXCR4 is a common feature shared by CD4 and CD8α, but not
by the MHC-II or the IL2Rα molecules. These results strongly
argue for the specificity of the CD4 and CD8α interactions with
CXCR4.
An additional experiment was conducted in which a CD4
chimera retaining the extracellular domain of CD4 and
composed of the transmembrane and cytoplasmic domains of
CD3γ (CD433) was used (Fig. 2). As a control, the CD488
chimera was also used in this experiment. The use of these
chimerae allowed a more accurate interpretation of the results
because the same antibodies directed against the extracellular
domain of CD4 could be used in the immunoprecipitation and
the immunodetection of CD4 after Western blotting. Fig. 5C
shows that both wild-type CD4 and CD488 efficiently
coprecipitated CXCR4 (upper panel, lanes 1–3 and 4–6,
respectively). On the contrary, CD433 was not able to
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containing lysates were used in the assay (lanes 7–9). This
could not be attributed to a lower amount of CD433 as
compared with wild-type CD4 and CD488 (Fig. 5C lower
panel). Together, these data strongly suggest that both the CD4/
CXCR4 and CD8α/CXCR4 interactions are specific since none
of the other 1-TM proteins tested coprecipitated CXCR4.
Determination of the residues located in the cytoplasmic tail
of CD4 and CD8α involved in the interaction with CXCR4
Our findings clearly demonstrate that the CD4/CXCR4 and
CD8α/CXCR4 interactions are specific and depend upon the
cytoplasmic domains of CD4 and CD8α. We therefore tried to
identify a shared motif in the cytoplasmic domains of these
proteins that would explain their common ability to interact with
CXCR4. The analysis of the amino-acid sequence of CD4 and
CD8α revealed the presence of an RXRRR motif in the
membrane proximal cytoplasmic domain of both proteins (Fig.
2, R398H399R400–402 and R188N189R190–192, respectively). Two
CD4 constructs were generated to investigate the involvement
of the RHRRR motif in the interaction with CXCR4. A C-
terminal truncation at position 403 resulted in the first construct
(CD4 ΔCT2) missing all the residues downstream of the
RHRRR motif. The second construct (CD4 3R/A) has alanines
substituted for each of the arginines in the R400–402 motif in the
full-length CD4. The impact of these mutations on the CD4/
CXCR4 interaction was investigated in coprecipitation experi-
ments by mixing lysates of cells expressing CXCR4 and CD4
mutants as described previously. In agreement with our
previous results, Fig. 6A shows an efficient coprecipitation of
CXCR4 with wild-type CD4 but not CD4 ΔCT1 (upper panel
lanes 1 and 2). CD4 ΔCT2 was also able to coprecipitateFig. 6. Interaction between CXCR4 and CD4 and CD8α mutants. CXCR4 and the sp
cells. Cells were solubilized and the corresponding cleared lysates were then used
containing lysate (∼600 μg of total proteins) were incubated 1 h with lysates (∼600 μ
proteins. Protein A–Sepharose beads and 3 μg of OKT4 were then added to immuno
the Fig. 4A legend. (C) The interaction between wild-type or CD8 mutant pr
immunoprecipitated with 3 μg of 32-M4 and analyzed under non-reducing conditioCXCR4 to the same extent as wild-type CD4 (lane 3),
suggesting that the membrane proximal cytoplasmic domain
of CD4 retaining the RHRRR motif is sufficient to promote the
interaction of CD4 with CXCR4. Interestingly, CD4 3R/A was
also able to coprecipitate CXCR4 (lane 4) suggesting that
cytoplasmic motifs other than R400–402 also contribute to the
interaction of CD4 with CXCR4. Additional truncations were
performed in the context of the 3R/A mutant to help identify
CXCR4 binding determinants. CXCR4 coprecipitated ineffi-
ciently with CD4 3R/A, ΔCT3 (Fig. 6A, lane 5). However,
shorter C-terminal truncations (3R/A, ΔCT4-ΔCT6) allowed
the CD4 3R/Avariant to coprecipitate CXCR4 (lanes 6–8). This
experiment indicates that the K411R412 motif located between
the ΔCT3 and ΔCT4 truncation sites contributes to the CD4/
CXCR4 interaction in the CD4 3R/A context. To explore the
role of this motif in full-length CD4, alanine substitutions were
made for Lys-411 and Arg-412 in wild-type CD4 (CD4 KR/A)
or CD4 3R/A (CD4 A/A). The ability of these mutants to
coprecipitate CXCR4 was investigated as described previously.
Fig. 6B shows that the KR/A substitution in full-length CD4
only slightly affected the ability of the corresponding mutant to
coprecipitate CXCR4, compared with wild-type CD4 (upper
panel, compare lanes 3 and 1). This is consistent with the
previous finding that CD4 ΔCT2, which lacks the KR motif,
can coprecipitate CXCR4 to the same extent as wild-type CD4.
However, when both the 3R/A and KR/A alterations were
present, the ability of the corresponding mutant (CD4 A/A) to
interact with CXCR4 was dramatically reduced (lane 4).
Together, these data strongly suggest that the R400–402 and
K411R412 motifs in the CD4 cytoplasmic tail are the major
contributors to the CD4/CXCR4 interaction.
The contribution of the RNRRR motif in the CD8α
cytoplasmic tail to the CD8α/CXCR4 interaction wasecified CD4 and CD8 mutants were individually expressed in transfected 293T
in coprecipitation experiments as follows. (A, B) Fixed amounts of CXCR4-
g of total proteins) from cells expressing the indicated wild-type or mutant CD4
precipitate CD4. The immunoprecipitated material was analyzed as described in
oteins and CXCR4 was investigated as described in panel A. CD8α was
ns.
Fig. 7. Characterization of Cf2Th cell lines coexpressing CD4 mutants with
CXCR4 or CCR5. (A) Flow cytometry analysis for CD4, CXCR4 and CCR5
cell surface levels in Cf2Th cells expressing or coexpressing CXCR4 (left panel)
or CCR5 (right panel) with the indicated CD4 mutants. Cells were stained with
PE-coupled antibodies directed against CD4 (RPA-T4), CXCR4 (12G5) or
CCR5 (2D7), analyzed by flow cytometry and the mean fluorescence intensity
of the staining was recorded. For each cell line, CD4 expression levels were
normalized to that of cells expressing wild-type CD4, and CXCR4 or CCR5
expression levels were normalized to that of cells coexpressing these proteins in
the absence of CD4. (B) Cf2Th cell lines expressing or coexpressing the
indicated proteins were solubilized and immunoprecipitation were performed on
cleared lysates containing ∼600 μg of total proteins with 3 μg of anti-CD4
(OKT4), or ∼200 μg of total proteins with 2 μg of anti-CXCR4 (12G5) or anti-
CCR5 (2D7). CD4 immunoprecipitations were analyzed as described in the Fig.
4A legend. GPCR immunoprecipitations were analyzed by SDS-PAGE
followed by Western blotting and immunodetection.
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shows that wild-type CD8α but not CD8 ΔCT1 efficiently
coprecipitated CXCR4 (compare lanes 1 and 2), which is
consistent with our previous finding. However, in striking
contrast with what was observed with CD4, only weak CXCR4
coprecipitation was seen with CD8ΔCT2 and CD8 3R/A (lanes
3 and 4, respectively). These results indicate that the R190–192
motif is necessary but not sufficient to promote the interaction
between CD8α and CXCR4. The addition of sequences
carboxy-terminal to the RNRRR motif progressively restored
the ability of CD8α mutants to coprecipitate CXCR4 (lanes 5–
7), confirming the contribution of such elements to the CD8α/
CXCR4 interaction.
The CD4/CXCR4 interaction is not required for efficient
membrane fusion mediated by CXCR4-using HIV-1 envelope
glycoproteins
The affinity of CXCR4-using HIV-1 envelope glycoproteins
for their coreceptor was shown to be lower than that of CCR5-
using envelopes (Babcock et al., 2001; Wu et al., 1996). The
ability of CD4 to interact with CXCR4 might stabilize the more
labile interaction between the CD4/gp120 complex and
CXCR4. To investigate the contribution of the CD4/CXCR4
interaction to HIV-1 infection, we generated Cf2Th cell lines
coexpressing CXCR4 with forms of CD4 that interact (wild-
type CD4, CD4 ΔCT2) or do not interact with CXCR4 (CD4
ΔCT1, CD4 A/A).
Cell surface expression levels of CXCR4 and wild-type and
CD4 mutants were analyzed by flow cytometry. As can be seen
from Fig. 7A, and consistent with previously reported results,
CXCR4 was present in a native conformation on the surface of
Cf2Th cells (Babcock et al., 2001). The CXCR4 expression level
was not affected by the expression of wild-type CD4 or the
indicated mutants. Wild-type CD4 as well as the indicated
mutants were also detected on the surface of Cf2Th cells.
Interestingly, deletions made in the cytoplasmic domain of CD4
(ΔCT1 and ΔCT2) resulted in a higher steady-state expression
level of the corresponding mutants. This is similar to what has
been reported in T cell lines (Guillerm et al., 1998). The same
observations were made on Cf2Th cells coexpressing the CD4
mutants described above with CCR5. We next investigated the
ability of CD4 and CXCR4 to interact in Cf2Th cells. Fig. 7B
(upper panel) shows that wild-type and CD4 ΔCT2 coprecipi-
tated CXCR4 (lanes 3 and 5). Minimal or no coprecipitation
could be detected with CD4 ΔCT1 and CD4 A/A, respectively
(lanes 4 and 6). No coprecipitation of CCR5 could be detected in
Cf2Th cells coexpressing CCR5 with wild-type CD4 or the
indicated mutants (lanes 7–9). Of note, the amount of proteins
retrieved after the direct immunoprecipitations of CD4, CXCR4
and CCR5 (Fig. 7B, middle and lower panels) matched the
expression levels of these proteins determined by flow
cytometry (Fig. 7A). These coprecipitation data are consistent
with the results obtained in 293T cells (Figs. 3 and 6) and
validate the use of Cf2Th cell lines coexpressing CXCR4 and
CD4 to explore the role of the CD4/CXCR4 interaction in HIV-1
envelope-mediated membrane fusion mechanisms.Cf2Th cells coexpressing HIV-1 receptors and coreceptors
were infected with single-round reporter HIV-1 viruses
pseudotyped with various envelope glycoproteins. As expected,
Fig. 8A shows that HIV-1 viruses pseudotyped with the CCR5-
using YU2 envelope glycoproteins did not infect CXCR4-
expressing cells. Conversely, HIV-1 viruses pseudotyped with
the VSV-G envelope glycoprotein infected cells equally,
regardless of the mutant of CD4 coexpressed with CXCR4.
HIV-1 viruses pseudotyped with either HXBc2 or 89.6 envelope
glycoproteins also equivalently infected cells coexpressing
CXCR4 with the forms of CD4 able or unable to interact with
CXCR4. These results suggest that disrupting the interaction
between CD4 and CXCR4 does not impair HIV-1 entry.
Fig. 8. Investigation of the role of the CD4/CXCR4 interaction in HIV-1 envelope glycoprotein-mediated membrane fusion. (A) Single-round reporter HIV-1 viruses
carrying the gene encoding firefly luciferase and pseudotyped with the VSV-G, HXBc2, YU2 or 89.6 envelope glycoproteins were incubated with Cf2Th cells
coexpressing CXCR4 with the indicated wild-type or mutant CD4 proteins. Sixty hours post-infection, luciferase activity in target cells was analyzed and plotted in
light units (LU). (B) The same experiment was carried out as in panel A with viruses pseudotyped with the 89.6 envelope glycoprotein, in the presence of various
concentrations of the entry inhibitor BMS-806. Data were normalized to viral infection in the absence of drug. (C) 293T cells coexpressing the α fragment of β-
galactosidase with the HXBc2, YU2 or 89.6 envelope glycoproteins were incubated with Cf2Th cells coexpressing the ω fragment of β-galactosidase with CXCR4
and the indicated wild-type or mutant CD4 proteins. Twelve hours later, the formation of syncytia was assessed by measuring the activity of reconstituted β-
galactosidase, and plotted in LU. (D) The same experiment was carried out as in panel C with 293T cells expressing the 89.6 envelope glycoprotein, in the presence of
various concentrations of the entry inhibitor BMS-806. Data were normalized to syncytium formation in the absence of drug.
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whether the interaction between CD4 and CXCR4 confers an
advantage for HIV-1 entry when a selective pressure is exerted
during the fusion process. To this end, Cf2Th cell lines were
infected with single-round reporter HIV-1 viruses as in Fig. 8A,
in the presence of increasing concentrations of entry inhibitors
targeting gp120 (BMS-806 and IgG1-b12) or gp41 (T20). Fig.
8B shows that BMS-806 efficiently inhibited the infection of
cells coexpressing wild-type CD4 with CXCR4 by HIV-1
viruses pseudotyped with the 89.6 envelope glycoproteins. The
inhibition profile was identical whether cells expressed forms of
CD4 able or unable to interact with CXCR4; an IC50 of
approximately 5 nM was calculated for all the cell lines studied,
in agreement with published results (Madani et al., 2004;
Reeves et al., 2005; Si et al., 2004). The IC50 of each inhibitor
for HIV-1 viruses pseudotyped with HXBc2 and 89.6 envelope
glycoproteins is shown in Table 1. Slight variations in the
potency of drugs to inhibit entry of different viruses were seen;
however, these differences were not significant, taking into
account the standard variations calculated from experiments
performed multiple times.
Because HIV-1 entry is believed to involve a small number of
fusion events (Yang et al., 2005), subtle differences in the ability
of various forms of CD4 to engage in the membrane fusion
process might not be detected by entry assays. Syncytium
formation, which involves a larger number of fusion events, was
studied by coculturing the Cf2Th cell lines described above with
293Tcells transiently expressing HIV-1 envelope glycoproteins.
As expected, little fusion could be detected when Cf2Th cell
lines coexpressing CD4 and CXCR4were incubated with mock-transfected 293T cells or cells expressing the CCR5-using YU2
envelope glycoprotein (Fig. 8C). Conversely, 293T cells
expressing HXBc2 or 89.6 envelope glycoproteins efficiently
formed syncytia with Cf2Th coexpressing CXCR4 and wild-
type CD4 but not with cells expressing CXCR4 alone (not
shown). The CD4 mutants (CD4 ΔCT1 and CD4 A/A) that do
not interact with CXCR4 were as efficient as wild-type CD4 and
CD4 ΔCT2 in supporting syncytium formation. The effect of
entry inhibitors was also investigated on syncytium formation.
Fig. 8D shows that BMS-806 efficiently inhibited syncytium
formation between 293T cells expressing 89.6 and Cf2Th cells
coexpressing CXCR4 and wild-type CD4. The slight differences
in susceptibility to BMS-806 did not correlate with the ability of
CD4 to interact with CXCR4. Moreover, the same rank order of
susceptibility to BMS-806 was also found when syncytium
formation was analyzed between 293T cells expressing the 89.6
envelope glycoprotein and Cf2Th cells coexpressing CCR5 and
wild-type CD4 or CD4 mutants. This suggests that these
differences most likely represent intrinsic CD4 properties in the
context of syncytium formation inhibition by BMS-806. Table 1
reports the IC50 values of the entry inhibitors in the context of
syncytium formation and shows that no correlation can be made
between the ability of CD4 to interact with CXCR4 and
susceptibility to the inhibitors.
Together, these data show that the fusion process involving
CXCR4-using HIV-1 envelope glycoproteins expressed at the
surface of transfected 293T cells, or present on the surface of
virions, with CXCR4 and CD4 expressed on the surface of
Cf2Th cells is independent of the ability of CD4 to interact with
CXCR4.
Table 1




Coreceptor Inhibitor Virus entry a Cell–cell fusion b
CD4 wt CD4 ΔCT1 CD4 ΔCT2 CD4 A/A CD4 wt CD4 ΔCT1 CD4 ΔCT2 CD4 A/A
HXBc2 CXCR4 T20 0.20 μMc 0.10 μMc 0.20 μMc 0.10 μMc 0.24 ± 0.11 μM 0.06 ± 0.04 μM 0.17 ± 0.12 μM 0.15 ± 0.09 μM
BMS-806 1.65 ± 0.35 nM 1.40 ± 0.60 nM 1.05 ± 0.05 nM 1.40 ± 0.60 nM 0.91 ± 1.06 μM 0.63 ± 0.30 μM 4.67 ± 6.69 μM 0.21 ± 0.15 μM
IgG1-b12 0.06 nMc 0.08 nMc 0.10 nMc 0.06 nMc >100 nM >100 nM >100 nM >100 nM
AMD3100 N/D N/D N/D N/D 1.62 ± 1.39 μM 0.21 ± 0.19 μM 0.41 ± 0.39 μM 0.46 ± 0.44 μM
89.6 CXCR4 T20 0.13 ± 0.08 μM 0.13 ± 0.08 μM 1.25 ± 0.75 μM 0.15 ± 0.05 μM 11.3 ± 7.4 μM 2.07 ± 1.10 μM 10.7 ± 7.4 μM 5.73 ± 3.98 μM
BMS-806 5.00 ± 3.00 nM 5.00 ± 2.00 nM 4.50 ± 2.50 nM 4.50 ± 1.50 nM 1.52 ± 1.22 μM 2.08 ± 2.49 μM 19 ± 16.5 μM 5.73 ± 3.98 μM
IgG1-b12 1.20 ± 0.80 nM 1.25 ± 0.25 nM 1.65 ± 0.15 nM 1.15 ± 0.35 nM >100 nM >100 nM >100 nM >100 nM
AMD3100 N/D N/D N/D N/D 0.35 ± 0.26 μM 0.22 ± 0.15 μM 0.36 ± 0.24 μM 0.21 ± 0.16 μM
YU2 CCR5 T20 26.5 ± 3.5 μM 19.5 ± 0.5 μM 22.0 ± 1.0 μM 22.0 ± 1.0 μM 2.38 ± 1.48 μM 1.54 ± 1.08 μM 1.80 ± 0.99 μM 1.58 ± 1.44 μM
BMS-806 2.35 ± 0.05 nM 3.15 ± 0.55 nM 3.45 ± 0.25 nM 2.15 ± 0.15 nM 0.48 ± 0.21 μM 0.78 ± 0.31 μM 0.90 ± 0.65 μM 0.66 ± 0.78 μM
IgG1-b12 10.0 ± 0.0 nM 9.5 ± 0.50 nM 12.0 ± 2.0 nM 11.5 ± 2.5 nM >100 nM >100 nM >100 nM >100 nM
TAK779 N/D N/D N/D N/D 30 μMc 20 μMc 22 μMc 9 μMc
89.6 CCR5 T20 2.10 ± 1.10 μM 2.10 ± 0.90 μM 2.30 ± 1.70 μM 2.10 ± 1.10 μM 1.32 ± 0.61 μM 2.30 ± 2.72 μM 4.25 ± 3.42 μM 0.83 ± 0.33 μM
BMS-806 18.0 ± 8.0 nM 12.5 ± 9.5 nM 16.5 ± 3.5 nM 19.0 ± 7.0 nM 0.22 ± 0.10 μM 0.40 ± 0.23 μM 2.88 ± 1.93 μM 0.11 ± 0.03 μM
IgG1-b12 1.65 ± 0.25 nM 1.50 ± 0.10 nM 1.80 ± 0.20 nM 1.60 ± 0.20 nM >100 nM >100 nM >100 nM >100 nM
TAK779 N/D N/D N/D N/D 0.50 ± 0.41 μM 0.60 ± 0.30 nM 1.35 ± 0.85 μM 0.55 ± 0.35 μM
HIV-1 entry and syncytium formation were assessed for the HIV-1 envelope glycoproteins and coreceptors indicated in columns 1 and 2, respectively, in the presence of the inhibitors listed in column 3. The forms of CD4
co-expressed on the target cells with coreceptors are indicated on the following columns. IC50 values were determined as described in the text, and averages followed by standard deviations are reported.
N/D, not determined.
a Experiments were performed at least twice unless otherwise indicated.
b Experiments were performed at least three times unless otherwise indicated.
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In this study, we investigated possible interactions between
the primary receptor (CD4) and coreceptors (mainly CCR5 and
CXCR4) used by HIV-1 to infect cells. A CD4/CXCR4 complex
could be precipitated with antibodies directed against the
extracellular domains of either protein. No significant copreci-
pitation of CCR5 and CD4 could be detected under similar
experimental conditions. The CXCR4 interaction site on CD4
was mapped to the R400–402 and K411R412 motifs located in the
CD4 cytoplasmic domain. Alanine substitutions for the basic
residues in both motifs severely decreased the ability of CD4 to
interact with CXCR4 but did not affect HIV-1 entry into cells
coexpressing CXCR4 and this CD4 mutant.
The literature reports conflicting data about a possible
interaction between CD4 and HIV-1 coreceptors. In agreement
with our results, several groups have described an association
between CXCR4 and CD4 in U937 cells and peripheral blood
lymphocytes (Mbemba et al., 2002; Zaitseva et al., 2005) and in
CEMT4 cells (Sloane et al., 2005). A CCR5-dependant association
between CXCR4 and CD4 expressed in NIH3T3 cells has also
been described (Wang et al., 2004). Conversely, Xiao et al. did not
detect any interaction between CD4 and CXCR4 coexpressed in
NIH3T3 (Xiao et al., 1999). These discrepancies could be
explained by a differential conformation of CD4 or CXCR4 due
to cell type-specific post-translational modifications of these
proteins (Lapham et al., 2002; Sloane et al., 2005; Zaitseva et al.,
2003). Indeed, Sloane et al. reported recently that alteration of the
asparagine glycosylation sites in CXCR4 (Asn11 and Asn176)
decreased the ability of CXCR4 to interact with CD4 (Sloane et al.,
2005). Cell type-specific post-translational modification of CCR5
might also explainwhywe could not detect a significant association
between CD4 and CCR5 either in 293T cells (Figs. 1, 4–6) or in
Cf2Th cells (not shown), whereas others have detected an
interaction between CD4 and CCR5 expressed in primary T cells,
NIH3T3 and HOS cells (Wang et al., 2004; Xiao et al., 1999).
Because of the susceptibility of CXCR4 mutants to misfolding
and/or instability in detergents (Ahr et al., 2005; Baribaud et al.,
2001; Brelot et al., 1997; Doranz et al., 1999; Roland et al., 2003;
Basmaciogullari and Sodroski, unpublished results), we confined
our mutagenic analysis to CD4. We showed that the R400–402 and
K411R412 motifs in the CD4 cytoplasmic tail are the main
contributors to the CD4/CXCR4 interaction. Secondary structure
predictions and functional studies have reported a putative α-helix
in the cytoplasmic domain of CD4 (Gratton et al., 1996; Tiganos et
al., 1997; Yao et al., 1995). This was further confirmed by circular
dichroism and NMR spectroscopy studies where the cytoplasmic
domain of CD4 encompassing amino acids 403 to 417 was shown
to have the characteristics of an amphipathic α-helix (Kim
et al., 2003; Wray et al., 1998). According to these results, the
R400–402 motif resides in an unstructured region of the membrane
proximal cytoplasmic domain of CD4, whereas the K411R412 motif
is locatedwithin theα-helix. Even though it has been suggested that
this α-helix might bind the inner face of the plasma membrane
(Wray et al., 1998), it also appears to be accessible to intracellular
kinases because phosphorylation of Ser-408 occurs in vivo (Pitcher
et al., 1999). Moreover, the HIV-1 proteins Nef and Vpu have alsobeen shown to target the L413L414 (Aiken et al., 1994; Salghetti et
al., 1995) and the L414SEKKT419 (Bour et al., 1995; Tiganos et al.,
1997) motifs, respectively. It is thus conceivable that the K411R412
motif is available for protein interaction in intact cells. A functional
interaction has been described between the Src-family kinase Lck
and aCXCmotif located in the cytoplasmic tails of CD4 andCD8α
(Barber et al., 1989; Rudd et al., 1988; Shaw et al., 1989, 1990;
Turner et al., 1990; Veillette et al., 1988). Our preliminary results
suggest that Lck and CXCR4 do not compete for CD4 binding (not
shown). This is consistent with the fact that the Lck binding site on
CD4 (C420QC422) is located C-terminal to the R400–402 and
K411R412 motifs. Moreover, based on NMR spectroscopy studies
performed on peptides derived from the amino-terminus of Lck and
the cytoplasmic domain of CD4 (Kim et al., 2003), the side chains
of the Lys-411 andArg-412 residues extend away from the docking
site of Lck.
In our efforts to characterize the CD4/CXCR4 interaction, we
discovered that CXCR4 can also form a stable complex with
CD8α. Similar to what was observed for CD4, we found that the
CD8α/CXCR4 interaction is also governed by an arginine-rich
motif (R190–192) in addition to more C-terminal sequences not
mapped in this study. However, two main differences between
CD4 and CD8α structures involved in CXCR4 association are
evident. First, the contribution of the two motifs to the
interaction with CXCR4 differs. The interaction of CD4 with
CXCR4 requires the presence of one motif only, whereas both
motifs are required for the formation of a stable CD8α/CXCR4
complex. Second, the Lck binding site on CD8α (C194KC196) is
located between the twomotifs important for CXCR4 binding. It
would thus be interesting to determine how the presence of Lck
can affect the interaction between CD8α and CXCR4.
Previous studies performed in our laboratory have clearly
demonstrated that the conformation of CXCR4 is preserved in
CHAPSO and that of CCR5 in CHAPSO or Cymal-5
(Babcock et al., 2001; Basmaciogullari et al., 2002; Mirzabe-
kov et al., 1999). Immunoprecipitation experiments were thus
conducted on cells solubilized in a buffer containing 1%
CHAPSO, which is compatible with native conformations for
both molecules. We found that the CD4/CXCR4 complex
could form when lysates of cells expressing CXCR4 alone
were incubated with lysates of cells expressing CD4 alone.
Interestingly, the formation of this complex was prevented by
the binding of OKT4 or Q4120 antibodies to CD4 prior to the
incubation of CD4 with CXCR4. Given the location of the
CD4 epitopes recognized by these mAbs, this inhibition is
unlikely to be due to steric hindrance exerted by OKT4 or
Q4120 on CXCR4 binding. It rather suggests that the binding
of these mAbs might induce conformational changes in the
cytoplasmic domain of CD4 responsible for a weakened CD4/
CXCR4 interaction. Consistent with this hypothesis, it has
been shown on intact T cells that the binding of mAbs to the
extracellular domain of CD4 can transduce signals of different
kinds (apoptosis, activation, anergy), depending on the CD4
epitope targeted (Baldari et al., 1995; Briant et al., 1999).
Interestingly, the formation of the CD8α/CXCR4 complex
was also impaired by the binding of an anti-CD8 mAb to the
CD8α ectodomain prior to the incubation with CXCR4. This
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CD8α/CXCR4 interactions.
In light of our results showing a specific CD4/CXCR4
interaction, we investigated whether this interaction might
contribute to HIV-1 envelope glycoprotein-mediated mem-
brane fusion. Our results suggest that membrane fusion
involving HIV-1 receptors and coreceptors coexpressed on
Cf2Th cells and HIV-1 envelope glycoproteins either present
on virions or expressed on 293T cells is independent of the
cytoplasmic tail of CD4 and thus independent of the CD4/
CXCR4 interaction. For primary isolate-derived HIV-1
envelope glycoproteins, virus entry is strongly influenced
by the amount of CD4 and coreceptors expressed on target
cells (Bannert et al., 2000; Kozak et al., 1997; Platt et al.,
1998). Therefore, the contribution of the CD4/CXCR4
interaction on the fusion process might not be evident in
Cf2Th cells expressing high levels of these molecules and
become more important on cells expressing limiting amounts
of both CD4 and CXCR4. The contribution of the CD4/
CXCR4 interaction to optimal membrane fusion might also
be cell type-specific and depend on the viral entry route. In
addition to fusion at the cell surface, it has been suggested
that HIV-1 entry can take place in endocytic vesicles, prior
to vesicle acidification (Daecke et al., 2005; Fackler and
Peterlin, 2000; Fredericksen et al., 2002; Schaeffer et al.,
2004). The CD4/CXCR4 interaction might allow a better
concentration and cosorting of these molecules to the same
endocytic compartment and thereby contribute to this entry
pathway. Finally, the association of CD4 and CXCR4
provides a natural explanation for the selection of CXCR4
as a second receptor during the evolution of primate immu-
nodeficiency viruses.
Given that CD8α also interacts with CXCR4, the CD4/
CXCR4 and CD8α/CXCR4 interactions might play a role in the
formation of the immunological synapse, which involves
peptide-loaded MHC molecules APCs and the TCR complex,
with either CD4 or CD8, on the T cell. In support of this
hypothesis, crosstalk between signaling pathways of CXCR4,
the TCR and CD4 has been described (Peacock and Jirik, 1999;
Ticchioni et al., 2002; Van Drenth et al., 2000). The recruitment
of CXCR4 at the immunological synapse on T cells has also
been described (Molon et al., 2005) and might mirror the
presence of the so-called “tetraspan web” embedding MHC
molecules at the site of the synapse on APC, and play a role at
the structural level in stabilizing the APC-T cell interface (Claas
et al., 2001; Kropshofer et al., 2002; Vogt et al., 2002). Further
studies will be required to understand the circumstances in
which the observed CD4/CXCR4 interaction might play a role




Plasmids encoding CD4, CD8α and CD3 chimerae were
described earlier (Bour et al., 1999). In this study, chimericproteins are named according to the origin of their extracellular,
transmembrane and cytoplasmic domains (for example, CD433
refers to a chimera composed of the extracellular domain of
CD4 and the transmembrane and cytoplasmic domain of CD3).
Plasmids encoding MHC-II molecules (DRα and DRβ*1501
chains) and IL2Rα were given by K. Wucherpfennig and W.
Marasco (Harvard Medical School), respectively. All mutations
in CD4 and CD8α were done with the QuickChange site-
directed mutagenesis kit (Stratagene). Plasmids encoding
CXCR4 and CCR5 were described earlier (Babcock et al.,
2001; Mirzabekov et al., 1999). The plasmid encoding the C5aR
was given by H. Choe (Harvard Medical School) (Farzan et al.,
2001).
Monoclonal antibodies (mAbs) used to immunoprecipitate
CXCR4 (12G5), CCR5 (2D7) and the C5aR (C85-4124) were
purchased from Pharmingen. CD4 was immunoprecipitated
using mAbs specific for domain 1 (D1), D4 or cytoplasmic
domain of CD4: QS4120 (Calbiochem), OKT4 (ATCC) and C-
18 (Santa Cruz Biotechnology, Inc.), respectively. The 32-M4
mAb (Santa Cruz Biotechnology, Inc.) was used to immuno-
precipitate CD8α. IL2Rα and MHC-II were immunoprecipi-
tated with mAbs C-20 (Santa Cruz Biotechnology, Inc.) and
EDU-1 (BioSource International, Inc.), respectively. The 1D4
mAb, which reacts with a C9 peptide, was obtained from the
National Cell Culture Center and was used at a concentration of
1 μg/ml to detect C9-tagged GPCR following Western blotting.
The Abs specific for the extracellular domains of CD4
(ImmunoDiagnostics, Inc.) and CD8α (H-160; Santa Cruz
Biotechnology, Inc.) were used at a concentration of 1 μg/ml to
detect proteins containing the extracellular domain of CD4 or
CD8α, respectively, following Western blotting. Secondary
reagents were peroxidase-coupled anti-mouse and anti-rabbit
IgG (Sigma), each used at a 1:2000 dilution. Monoclonal
antibodies used for cell surface staining and FACS analysis
were phycoerythrin (PE)-conjugated RPA-T4, 12G5 and 2D7,
purified IgG2a and IgG2b (Pharmingen), and PE-coupled goat
anti-human IgG (Jackson ImmunoResearch).
Transfections and metabolic labeling
For immunoprecipitation experiments, proteins of interest
were either coexpressed or individually expressed in 293T
cells, as indicated in the text. Cells were seeded at a density
of 3 × 104 cells/cm2 and transfected after 16 h by the calcium
phosphate precipitation technique. Typically, 5 ng of
plasmids/cm2 was used for GPCR expression (CXCR4,
CCR5 and C5aR), and 50 ng of plasmids/cm2 was used to
express all the other proteins described in this study. Carrier
DNA was used to bring the total amount of DNA to 250 ng/
cm2. MHC-II molecules expression was obtained by cotrans-
fecting cells with two plasmids encoding the DRα and the
DRβ chains (50 ng of each plasmid/cm2). Because the
CD488 and the CD433 constructs are under the transcrip-
tional control of the HIV-1 LTR, 293T cells were cotrans-
fected with a Tat-encoding plasmid (5 ng of plasmids/cm2) in
order to achieve expression levels similar to that of wild-type
proteins. When indicated, transfected cells were metabolically
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described elsewhere (Babcock et al., 2001).
Immunoprecipitations
Cells were harvested 48 h post-transfection with PBS
supplemented with 5 mM EDTA (PBS–EDTA), pelleted
and resuspended in solubilization buffer containing
100 mM (NH4)2SO4, 20 mM Tris (pH 7.5), 10% glycerol,
1% 3-[(-cholamidopropyl) dimethylammonio]-2-hydroxyl-1-
propanesulfonic acid [CHAPSO (Anatrace)] and 1 × complete
protease inhibitor mixture (Roche Molecular Biochemicals).
After a 30-min incubation at 4 °C under gentle agitation, cell
lysates were centrifuged at 14,000 × g for 30 min at 4 °C. The
soluble fraction was then assayed for protein content with the
DC protein assay kit (Bio-Rad) and stored frozen in aliquots at
−20 °C. Cells from 75-cm2 flasks were usually lysed in 500 μl
of solubilization buffer and yielded a protein content ranging
from 5 to 15 μg/μl. Immunoprecipitations were carried out in a
final volume of 500 μl with 15 μl of packed protein A–
Sepharose beads (Amersham Biosciences Corp) as described in
figure legends. All incubation steps were carried out at 4 °C
under gentle agitation. Beads were then washed 4 times in
solubilization buffer, and the immunoprecipitated material was
eluted by incubating the beads for 30 min at 37 °C in Laemmli
sample buffer prepared without β-mercapto ethanol (β-ME). As
indicated in the figure legends, CD4 analysis by SDS-PAGE
followed by immunodetection was performed under reducing
conditions. Samples were incubated 5 min at 95 °C in the
presence of 5% β-ME to reduce disulfide bonds. Proteins were
resolved by SDS-PAGE using precast 10% acrylamide
NuPAGE Novex Bis–Tris gels (Invitrogen) unless otherwise
indicated. Proteins were then visualized by fluorography or by
Western blotting followed by immunodetection.
Cell culture
293T cells were grown in complete medium [Dulbecco
modified Eagle's medium supplemented with 10% fetal calf
serum (FCS); 100 IU of penicillin/ml and 100 μg of
streptomycin/ml (Invitrogen)] at 37 °C with 5% CO2. Cell
lines stably coexpressing CD4 with CXCR4 or CCR5 were
obtained by transducing Cf2Th cells (ATCC) with recombi-
nant VSV-G-pseudotyped retroviruses as described elsewhere
(Perron et al., 2004), with minor modifications. The codon-
optimized cDNAs encoding C9-tagged CXCR4 and CCR5
were subcloned into the pMSCVpuro plasmid (Clonetech),
and the cDNA encoding wild-type and CD4 mutants were
subcloned into the pMSCVhyg plasmid (Clonetech). Recom-
binant viruses were obtained by cotransfecting 293T cells
with the pMSCV constructs, pVPack-GP and pVPack-VSV-G
packaging plasmids (Stratagene). Thirty-six hours post-
transfection, the supernatants containing the recombinant
viruses were collected and used to infect Cf2Th cells. Cells
were then expanded and selected in complete medium
supplemented with 4 μg/ml of puromycin (Clonetech) and
0.2 mg/ml of hygromycin (Roche Molecular Biochemicals).Cell surface staining and flow cytometry
Cells were harvested, washed once in PBS and incubated
30 min at 4 °C on ice in PBS supplemented with 2% FCS
(PBS-FCS). The following steps were then carried out at
4 °C. For Cf2Th cell surface staining, ∼106 cells were
pelleted, resuspended in 20 μl of PE-coupled RPA-T4, 12G5
or 2D7 antibody solution and incubated 45 min. Cells were
then washed twice in PBS-FCS, once in PBS and analyzed by
FACS. Jurkat cells were subjected to a two-step staining
protocol; approximately 2 × 106 cells were pelleted,
resuspended in 50 μl of PBS-FCS containing the antibodies
indicated in the figure legends and incubated 45 min. Cells
were then washed 3 times in PBS-FCS and incubated in PBS-
FCS supplemented with PE-coupled anti-mouse IgG (1:20).
After a 45-min incubation, cells were washed twice in PBS-
FCS, once in PBS and analyzed by FACS. All FACS analyses
were performed on a Becton Dickinson FACScan with the
CellQuest software.
HIV-1 entry assay
Single-round HIV-1 carrying the firefly luciferase gene
were made as described elsewhere (Madani et al., 2004).
Briefly, 293T cells were transfected by the calcium phosphate
precipitation technique with the HIV-1 packaging plasmid
(pCMVΔP1ΔenvpA), the HIV-1 vector encoding the firefly
luciferase (pHIV-1Luc), and the plasmids encoding the HIV-1
envelope glycoprotein variants (pSVIIIenv) at a 5:5:1 ratio
(0.3 μg DNA/cm2 total). In the case where viruses were
pseudotyped with the vesicular stomatitis virus (VSV) G
glycoprotein, the pHCMV-G plasmid and a Rev encoding
plasmid (1:1 ratio) were used instead of pSVIIIenv. Six hours
post-transfection, cells were washed and left in culture for
36 h after which the supernatants were collected, spun to
remove cells, divided into aliquots, and stored at −80 °C until
further use. HIV-1 entry was analyzed as follows. Cf2Th cells
coexpressing CD4 with CXCR4 or CCR5 were seeded at a
density of 6 × 103 cells/well in 96-well IsoPlates (PerkinEl-
mer). Twenty-four hours later, the cell culture medium was
removed, and viruses were added to the cells in a final
volume of 200 μl (the viral dilutions were normalized to give
∼5 × 106 LU per well on cells expressing wild-type CD4).
After 14 h, the medium was removed and replaced by fresh
complete medium, the cells were then left in culture, and
luciferase activity was assayed 48 h later, as described
elsewhere (Madani et al., 2004). In cases where inhibitors
where used, viral dilutions containing various concentrations
of inhibitor were preincubated 2 h at 37 °C and transferred to
cells.
Syncytium formation assay
Cf2Th cells stably coexpressing wild-type or CD4 mutants
with CXCR4 or CCR5 were seeded at a concentration of
1.3 × 105 cells/cm2. 293T cells were plated at 2 × 105 cells/
cm2. Sixteen hours later, the cells were transfected using
65S. Basmaciogullari et al. / Virology 353 (2006) 52–67Lipofectamin-2000 (Invitrogen) according to the instructions
of the manufacturer. 293T cells were cotransfected with
plasmids encoding the α fragment of β-galactosidase
(Holland et al., 2004), HIV-1 Tat and envelope glycoproteins
(0.1, 0.05 and 0.5 μg/cm2, respectively). In mock-transfected
cells, the pUC plasmid was used instead of the plasmid
encoding the HIV-1 envelope glycoproteins. Cf2Th cells were
transfected with the plasmid encoding the ω fragment of β-
galactosidase (Holland et al., 2004) (0.4 μg/cm2). Six hours
later, cells were washed once with complete medium and kept
in culture for 24 h. The cells were then harvested with PBS–
EDTA, washed once and resuspended in complete medium.
293T and Cf2Th cells were mixed in 96-well IsoPlates
(3 × 104 and 2 × 104 cells per well, respectively) in a final
volume of 200 μl/well. Syncytium formation was analyzed
12 h later by measuring the activity of reconstituted-β-
galactosidase in syncytia with the Galacto-Star System kit
(Applied Biosystems). Light emission was measured in a
microplate luminometer.
The T20 peptide was purchased from New England Peptide.
The BMS-806 compound was synthesized as described
elsewhere (Wang et al., 2003). The neutralizing mAb IgG1-
b12 was a kind gift of D. Burton (The Scripps Research
Institute). Drugs targeting CXCR4 and CCR5, AMD-3100 (JM-
2987) (Bridger et al., 1995; De Clercq et al., 1994; Hendrix et
al., 2000) and TAK-779 (Baba et al., 1999), respectively, were
obtained through the AIDS Research and Reference Reagents
Program, Division of AIDS, NIAID, NIH.References
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